Background: Recurrence in oesophageal cancer continues to remain high after curative surgery. The aim of
INTRODUCTION
Oesophagus cancer is the eighth most common cancer at worldwide level, and is the sixth main cause of death from cancer (1) . Surgery involving oesophagectomy is still the main therapeutic option (2, 3) , although even after receiving curative treatment the possibility of recurrence in patients, either locoregional or distant, is still high, with percentages varying between 29% and 59% (4-16).
Different factors affect the risk of recurrence, mainly the location of the tumour, the local stage of the tumour, the degree of cellular differentiation and the presence of metastasis on diagnosis (5) (6) (7) (8) (9) 11, 12, 14, 16) . It is important to understand the factors that favour the presence of tumour recurrence, as well as the different patterns of recurrence, in order to be able to design suitable therapeutic strategies for these patients.
The aim of this study was to demonstrate the characteristics and progress of patients with oesophageal cancer who have undergone curative surgery, as well as to study the risk factors for developing a recurrence.
Also, in patients with tumour recurrence, to analyse the different patterns of recurrence, their therapeutic management and their evolution.
MATERIALS AND METHODS

Study population
A total of 180 patients were diagnosed with anatomical-pathological confirmation of cancer of the oesophagus (CIE 9A: 150) at the University Hospital Complex in A Coruña (Spain) from 1 January 2003 to 31
December 2008. This study included all patients in the cohort (57 patients) who had undergone curative surgery, which enabled complete removal of the tumour along with the metastatic lymph nodes. A retrospective review of the patients' clinical records was carried out together with a prospective follow-up until 31 January 2012, in order to guarantee a minimum follow-up period of 3 years. The study excluded prevalent or recurring cases, multiple cancers, metastatic cancers, or those that had been treated and/or diagnosed at other hospitals.
Measurements
A study was made of the socio-demographic variables of the patient, their personal backgrounds, comorbidity variables using Charlson's comorbidity index, the symptoms present at diagnosis, location of the tumour, histopathological cell type and tumour stage (TNM, seventh edition) (17, 18) . As data on risk factors and symptoms were collected retrospectively from clinical records, we registered it if it was indicated in the clinical records, although we were unable to quantify the frequency and amount of cigarette or alcohol consumption, nor the number of kilograms lost.
An analysis was made of the treatment received, surgery, chemotherapy and radiotherapy.
Tumour recurrence was considered as the detection during the post-surgical follow-up period of reappearance of the neoplastic disease either locoregional, distant, or both. Locoregional recurrence was defined as a recurrence isolated to the area of the anastomosis (perianastomotic) or in lymph nodes in the mediastinum and upper abdomen (supraceliac). Distant recurrence was defined as any spread of disease beyond a locoregional recurrence. The recurrence-free interval was defined as the time from the curative surgery to the first recurrence (locoregional, distant or both). 
Sample size justification
The study included a total of 57 patients. This sample size makes it possible to detect as significant a Hazard Ratio of 2.85 or more with a prevalence of exposure of 50% and a censored data percentage of 50%
(confidence: 95%; Statistical power: 80%).
Statistical analysis
A descriptive study was made of the variables that were obtained. The global survival rate was calculated using the Kaplan-Meier methodology and recurrence-free survival using competing risks survival analysis.
Proportional hazard assumption was assessed graphically by visual judgement of the log-minus-log survival plots, as well as checking the significance of a time-dependent variable added to the regression model (by means of an interaction of survival time and each individual covariate) for quantitative covariates. The accumulated occurrence of tumour recurrence during the follow-up period was estimated, considering nonrecurrence mortality as a competitive event, using the method proposed by Kalbfleisch and Prentice (19) . The accumulated occurrence of tumour recurrence according to different characteristics was compared using the test proposed by Gray (20) . Finally, in order to identify which characteristics were associated with the risk of tumour recurrence, a multivariate analysis was carried out using the model proposed by Fine and Gray (21) .
All of the tests were carried out bilaterally, considering values of p < 0.05 as significant. The analyses were carried out using the programmes Epidat 3.1, SPSS 19.0 and R 2.15.1.
Ethics
The study was carried out according to the principles laid down in the Declaration of Helsinki and ensuring compliance with Spanish Law 29/2009, which "Regulates the use of and access to electronic medical records.
Confidentiality was maintained in accordance with the current Spanish Data Protection Law (15/1999). The study received written approval from the regional Ethics Committee for Clinical Research (code 2011/372 CEIC Galicia).
RESULTS
Characteristics of the patients studied
Out of the 57 patients included in the study, 87.7% were male. The mean age of the patients was 61.4 ± 10.3 years, and the mean Body Mass Index (BMI) was 25.2 ± 3.9 kg/m 2 . Twenty-two patients (38.6%) had a background of gastro-oesophageal reflux, 80.7% were smokers, 57.9% were alcohol drinkers, and 49.1% had both risk factors. The score on Charlson's comorbidity index age-adjusted was 2.7 ± 1.7, with 50.9% of the patients in a high comorbidity range (≥ 3 points).
Forty-six patients (82.1%) presented with dysphagia at the time of diagnosis. A lower thoracic localisation (> 30-40 cm from the incisors) was the most frequent, in 49.1% of the cases. In the case of the tumours, 40
(70.2%) corresponded to squamous cell carcinomas, and 17 (29.8%) to adenocarcinomas. Thirty-seven patients (72.6%) were at stage II-III at the time of diagnosis, and five patients (9.8%) had metastatic lymph nodes (stage IV). Thirty-four patients (59.6%) received only surgical treatment, while 40.4% received surgical and oncological treatment (chemotherapy and/or radiotherapy). In those cases, chemotherapy and radiotherapy were mainly applied for neoadjuvant purposes (76.5% and 69.6% respectively).
Progress of patients and likelihood of recurrence
The median follow-up period for the 57 patients who underwent curative surgery was 18.5 months (range:
0.3-92.4), with an overall chance of survival of 82.5% after six months, 59.2% after one year, and 23.1% after 5 years of follow-up.
During the follow-up, 28 (50.9%) patients were detected with recurrence. Figure 1 shows the different progress options following curative surgery, together with the probability of each of them in the different follow-up periods. In those patients who underwent curative surgery, the probability of being diagnosed with a tumour recurrence (locoregional tumour recurrence, distant recurrence or both) during the first year after surgery was 29.1%, while 25.5% of the patients died without presenting any recurrence. Therefore, 45.4% of the patients who underwent curative surgery were alive and remained disease-free one year after the surgery. Similarly, the probability of tumour recurrence five years after the surgery is 52.4%, while 29.6% of the patients have died without presenting any recurrence. Therefore, only 18% of the patients will be alive and disease-free five years after curative surgery.
Risk factors for recurrence
The risk factors for recurrence analysed are shown in table I. In the univariate analysis, the histopathologic cell type was not significantly associated with the probability of recurrence during the follow-up, nor any other variable studied, although it may be seen that patients with dysphagia on diagnosis, as well as patients in stages III-IV, had a higher probability of recurrence during the follow-up period, as shown in figure 2 . After carrying out a multivariate regression analysis, adjusting for gender, age, BMI, Crude Charlson's comorbidity index, smoking and alcohol consumption, histophathologic cell type, TNM classification and treatment, it was found that the TNM classification is associated with the presence of recurrence during follow-up in a statistically significant way (Table I ). In order to adjust for Age as a clinically relevant and confounding variable and avoid over-adjustment, we included in the model the Crude Charlson's comorbidity index.
Disease-free survival and recurrence pattern
In patients with recurrence (n = 28), the median for the disease-free interval was 8.5 months (range: 2.0-56.0).
After one year of follow-up, 57.1% of the recurrences were diagnosed and 82.1% after 2 years of follow-up, detecting the last recurrence in our series after 56 months of follow-up. On evaluating the recurrence pattern 
Management of patients with recurrence, and post-recurrence survival
Once recurrence had been detected, treatment with chemotherapy was given to 4 patients (14.3%), with radiotherapy to 8 patients (28.6%), and a combination of both in 1 patient (3.6%). A self-expanding oesophageal stent was fitted to 1 patient (3.6%), and the remaining 14 patients (50.0%) were given palliative management.
The median post-recurrence survival rate was 4.7 months. In the case of patients who received palliative care
or an oesophageal stent, the median post-recurrence survival rate was 2.9 months, however in the case of the patients who received chemotherapy, radiotherapy or a combination of both, the post-recurrence survival rate reached 6.5 months (p = 0.074). The global post-recurrence survival curve and the curve for each treatment are shown in figure 3 .
DISCUSSION
The recurrence of oesophageal cancer after curative surgery continues to be high. In this study, out of the total of 57 patients who underwent curative surgery, 50.9% had some kind of recurrence (locoregional recurrence and/or distant metastasis). This percentage concurs with those from other series published in Europe, in countries such as Great Britain, the Netherlands, France or Spain (7-10,13,16), or in Asia, in countries such as Japan or China (5, 6, 11, 12) .
After one year of follow-up, 53.6% of all of the recurrences were detected; 82.1% after two years, and 85.7%
after three years. The last recurrence documented in our series was after 56 months (4 years and 8 The majority of the studies analysed (5, 6, (8) (9) (10) (11) (12) (13) (14) 16) have found that the degree of tumour invasion, as well as the presence of metastatic lymph, are variables that are associated with the recurrence of the disease, and similarly, in our study the patients with higher stages had a higher probability of recurrence.
The median for the disease-free interval in our study was 8.5 months (range: 2.0-56.0). Generally, the value for this interval is closer to one year of follow-up, as seen in the studies of Hulscher et al. (7) (range: 1.1-48.0), a figure that was very close to that of our population (Table II) .
The prognosis for patients with recurrence is generally poor, with post-recurrence survival data of less than 12 months (6, 9, 12, 14) , varying between the median of 2.7 months from the study by Dresner et al. (8) in the UK, to the median of 11 months from the study of Lou et al. (15) in New York. In our study, the median for the post-recurrence survival rate was 4.7 months. Despite not finding any statistically significant differences, the post-recurrence survival rate in the patients who underwent more intensive treatment was significantly higher. Similar results were found by Abate et al. (14) in their study from 2010, where the median for the post-recurrence survival rate was 9 months in treated patients, compared to 3 months for patients who did not receive any treatment.
We believe that the limitations of this study are the fact that we do not have tumour markers that could play an important role in the prognosis of oesophageal cancer, and which would help to identify and predict the prognosis of this tumour, as well as to adapt the treatment individually to each patient.
In turn, we have verified that our results concur with those from more extensive series published at international level (8, 9, 13, 14) .
It is important to note that in our study we used the competitive risk methodology, which is appropriate for analysing the behaviour of a person who may experience different events during the follow-up of the disease, and that we also provide data on oesophageal cancer, an illness that has a high incidence and mortality rate, and for which there is little data at population level in our region.
CONCLUSIONS
This study shows that the recurrence of oesophageal cancer is very frequent, despite undergoing curative surgery. Most recurrences will occur during the 2 years after surgery, meaning that strict follow-up is essential during this period. After diagnosis of a recurrence the prognosis is poor, which means that subsequent studies are necessary to evaluate the different treatments, as well as the different tumour and genetic markers, in order to individually adapt the treatment to these patients.
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